^
    over3years
    [VIRTUAL] Next generation sequencing reveals the genetic landscape of PTPN11 in Chinese lung cancer patients (ESMO 2021)
    Several SHP2 allosteric inhibitors, such as ICP-189 and RMC-4630, have been entered into clinical trials. The mutational characteristics of PTPN11 in Chinese lung cancer population was first revealed in this study, which provides a broad range of scenarios for the future clinical application of SHP2 inhibitors in lung cancer.
    Clinical • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR1 (Fibroblast growth factor receptor 1) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ROS1 fusion • NTRK fusion
    |
    vociprotafib (RMC-4630) • ICP-189